VCNX News and Press, Vaccinex Inc. From 02/21/24

Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against challenging multi-pass membrane targets ROCHESTER, N.Y., Feb. 21, 20...

2024-02-19 08:02:11 ET Vaccinex Inc (VCNX) announced stock split at a ratio of 1-for-14 on 2024-02-20 ... Full story available on KlickAnalytics.com

2024-02-07 08:19:14 ET More on Vaccinex Financial information for Vaccinex Read the full article on Seeking Alpha For further details see: Vaccinex prices $3.7M PIPE financing

ROCHESTER, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammat...

2024-01-10 17:37:03 ET More on Vaccinex Financial information for Vaccinex For further details see: Vaccinex files to sell 712,484 shares for holders

2023-12-04 11:25:49 ET More on Vaccinex Vaccinex slumps 29%, prices $9.6M equity Financial information for Vaccinex For further details see: Vaccinex says Nasdaq gives co extension to regain compliance with listing rule

Company Has Reassured Nasdaq of Actions It Plans to Take to Meet Minimum Bid Price Requirement Randomized Phase 2 Study in Alzheimer’s Disease on Schedule to Complete Treatment in June 2024 ROCHESTER, N.Y., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a cl...

2023-11-13 17:30:47 ET More on Vaccinex Vaccinex slumps 29%, prices $9.6M equity Financial information for Vaccinex For further details see: Vaccinex GAAP EPS of -$1.09, revenue of $0.02M

Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Company raised over $10 million of new financing during Q3 and early October 2023. ROCHESTER, N.Y., Nov. 13, 2023 (GL...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...